ACT1
RQPKIWFPNRRKPWKKRPRPDDLEI-acid
Description
Application Data
Description
-
α-connexin carboxyl terminal peptide that specifically targets and maintains Cx43 at gap junction sites between cell-cell membrane borders of breast cancer cell. Thus it augments gap junction activity and impairs proliferation and survival of breast cancer cells with no effect on non-transformed cells.
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001536 Molecular Weight 3255.8 Sequence (one letter code) RQPKIWFPNRRKPWKKRPRPDDLEI-acid
Sequence (three letter code) H-Arg-Gln-Pro-Lys-Ile-Trp-Phe-Pro-Asn-Arg-Arg-Lys-Pro-Trp-Lys-Lys-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH
Aliase ACT1 peptide, α-connexin carboxyl terminal peptide Modifications Antennapedia attached for cell permeability Purity >95% Storage -20°C References Grek et al (2015) Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer 15 296. PMID: 25881004
Manufactured in: United Kingdom α-connexin carboxyl terminal peptide that specifically targets and maintains Cx43 at gap junction sites between cell-cell membrane borders of breast cancer cell. Thus it augments gap junction activity and impairs proliferation and survival of breast cancer cells with no effect on non-transformed cells.